AC Immune (STU:IMR) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IMR AC Immune SA STU:IMR
32 GF Score
Price €2.10
GF Value €0.65
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune FFO per Share?

FFO per Share only applies to REITs.

STU:IMR
32GF Score
AC Immune SA STU:IMR
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AC Immune (STU:IMR) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of €2.10 is trading 222.3% above its estimated GF Value™ of €0.65. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for STU:IMR:

  • FFO per Share:
  • GF Value™: €0.65 vs. price of €2.10 (222.3% above fair value)
  • GF Score™: 32/100 with 6 warning signs

No single metric tells the full story. See the STU:IMR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges ACIU:USA
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
32GF Score

Get the complete analysis for STU:IMR

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.10
Price
€0.65
GF Value